RxDoctor Payments Data

Joshua Garrett, MD

Family Medicine · Demorest, GANPI 1437174570

Payments from drug & device makers

$5,637in general payments, 2019–2025

Across 316 payments — averaging $17.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$651
  • Pfizer$454
  • Lilly USA, LLC$437
  • AstraZeneca$390
  • GSK$295
  • plus $2K from 36 others

What the payments were for

  • Consulting fees$1202%
  • Food & beverage$5,51698%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,637 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$119,646
Medicare patients
315
Services billed
2,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide112$131,581
EliquisApixaban91$116,349
XareltoRivaroxaban101$93,146
JanuviaSitagliptin Phosphate59$63,912
JardianceEmpagliflozin57$51,631
FarxigaDapagliflozin Propanediol39$43,295
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$41,661
MyrbetriqMirabegron39$39,941
Tresiba Flextouch U-200Insulin Degludec44$39,123
Repatha SureclickEvolocumab37$31,142
TradjentaLinagliptin33$23,803
ShingrixVaricella-Zoster Ge/As01b/Pf98$21,297
Novolog FlexpenInsulin Aspart48$19,490
Praluent PenAlirocumab14$18,050
GlyxambiEmpagliflozin/Linagliptin11$15,760

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$651$131,581112 claims
PfizerEliquis, Abrysvo$454$121,221107 claims
Johnson & JohnsonXarelto$137$93,146101 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$264$91,194101 claims
GSKTrelegy Ellipta, Shingrix, Arexvy$295$71,701169 claims
MerckJanuvia$99$63,91259 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$390$57,22662 claims
Astellas Pharma US IncMyrbetriq$12$39,94139 claims
Lilly USA, LLCTrulicity$437$13,78615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Demorest

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →